Table 1.
Demographic and clinical characteristics.
| Characteristics | No (%) | p-Value a | |||
|---|---|---|---|---|---|
| Patients (n = 67) |
Cases (n = 74) |
Toxicity (n = 34) |
No toxicity (n = 40) |
||
|
Age at treatment (years), mean ± SD <60 60–69 70–79 >80 |
75 ± 7.8 2 (3) 15 (22) 30 (45) 20 (30) |
75 ± 7.9 2 (3) 16 (22) 33 (45) 23 (31) |
74 ± 7.8 2 (6) 6 (18) 17 (50) 9 (26) |
76 ± 7.9 0 10 (25) 16 (40) 14 (35) |
0.3 0.3 |
|
Race
White Black Other |
44 (66) 19 (28) 4 (6) |
50 (68) 20 (27) 4 (5) |
22 (65) 10 (29) 2 (6) |
28 (70) 10 (25) 2 (5) |
0.9 |
|
BMI (kg/m2), median (IQR) <18.5 18.5–24.9 25–29.9 30–34.9 35–39.9 40–44.9 |
28 (26–32) 0 14 (22) 26 (41) 15 (24) 5 (8) 3 (5) (n = 63) |
28 (26–33) 0 16 (23) 28 (41) 17 (25) 5 (7) 3 (4) (n = 69) |
27 (25–31) 0 8 (26) 11 (35) 8(26) 4 (13) 0 (n = 31) |
28 (26–31) 0 8 (21) 17 (45) 9 (24) 1 (3) 3 (8) (n = 38) |
0.7 0.8 |
| Pretreatment PSA, median (IQR) | 6.1 (2.2–18) | 6.5 (2.3–18) | 8.1 (2.8–29) | 5.2 (2.2–14) | 0.1 |
| Prior treatment | |||||
| Radical prostatectomy Prostate SBRT |
20 (30) 63 (94) |
20 (27) 70 (95) |
10 (14) 32 (43) |
10 (14) 38 (51) |
0.8 >0.99 |
|
Current ADT
Yes No |
50 (75) 17 (15) |
54 (73) 20 (27) |
28 (82) 6 (18) |
26 (65) 14 (35) |
0.1 |
|
Pre-SBRT imaging
PSMA Axumin MRI/CT |
25 (37) 33 (49) 9 (13) |
28 (38) 37 (50) 9 (12) |
14 (41) 16 (47) 4 (12) |
14 (35) 21 (52) 5 (12) |
0.9 |
|
Hormone sensitivity
Castrate sensitive Castrate resistant |
57 (85) 10 (15) |
64 (86) 10 (14) |
26 (76) 8 (24) |
38 (95) 2 (5) |
0.04 |
|
Target volumes
Boost No boost |
33 (49) 34 (51) |
36 (49) 38 (51) |
16 (47) 18 (53) |
20 (50) 20 (50) |
0.8 |
|
# of involved lymph nodes
Mean ± SD Median (IQR) |
4.2 ± 3.7 3 (2-6) (n = 66) |
4.2 ± 3.6 3 (2-6) (n = 73) |
5.6 ± 4.1 4 (2-8) (n = 33) |
3.2 ± 2.8 2 (1-4) |
0.004 |
|
Location of radiation
Abdomen Pelvis Abdomen + pelvis |
17 (25) 28 (42) 22 (33) |
20 (27) 31 (42) 23 (31) |
12 (35) 9 (26) 13 (38) |
8 (20) 22 (55) 10 (25) |
0.045 |
BMI, body mass index; IQR, interquartile range; PSA, prostate-specific antigen; SBRT, stereotactic body radiotherapy; ADT, androgen deprivation therapy; PSMA, prostate-specific membrane antigen.
a
p-Values for the comparison between patients with and without toxicity were calculated using Wilcoxon rank sum test and Fisher’s exact test for non-normally distributed continuous and categorical variables, respectively. The bolded values indicate that they are statistically significant.